Statistics

Total Visits

Views
FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-alpha blockers in psoriatic arthritis: A longitudinal study with 6 months of followup69

Select a period of time:

Number of views in the range

Views
FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-alpha blockers in psoriatic arthritis: A longitudinal study with 6 months of followup38

Views

Views
February 20256
March 202513
April 20253
May 20251
June 20252
July 202513
August 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States15
Singapore14
Brazil3
United Kingdom2
Egypt1
Spain1
France1
Mexico1
 

Top cities views

Views
Cairo1
Conyers1
Council Bluffs1
Gulf Breeze1
Juiz de Fora1
Neuilly-Plaisance1
Pittsburgh1
Portland1
São Paulo1
Thomasville1